Payment overview · 2025
General Payments
$162.88
8 reported records · 6 companies
Healthcare provider profile · identity verified
Khalid Rashid Butt, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BAINBRIDGE, NY · NPI 1982676060
Verified facts
What the public records show
CMS Open Payments records show Khalid Rashid Butt, M.D. received $162.88 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.18 | 25.3% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $35.69 | 21.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.63 | 18.8% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $20.35 | 12.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.28 | 11.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.75 | 10.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $162.88 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $35.69 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $30.63 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $30.63 | 2 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $30.63 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 266 | 86 |
| Lisinopril | Lisinopril | 252 | 81 |
| Simvastatin | Simvastatin | 230 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 181 | 57 |
| Omeprazole | Omeprazole | 168 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 35 |
| Sertraline Hcl | Sertraline Hcl | 118 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 29 |
| Gabapentin | Gabapentin | 97 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 56 |
| Losartan Potassium | Losartan Potassium | 87 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 26 |
| Metformin Hcl | Metformin Hcl | 80 | 28 |
| Ramipril | Ramipril | 77 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 18 |
| Carvedilol | Carvedilol | 71 | 22 |
| Eliquis | Apixaban | 70 | 25 |
| Furosemide | Furosemide | 70 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 66 | 32 |
| Alendronate Sodium | Alendronate Sodium | 64 | 18 |
| Glipizide | Glipizide | 62 | 20 |
| Meloxicam | Meloxicam | 62 | 20 |
| Metformin Hcl Er | Metformin Hcl | 62 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 57 | 14 |
| Prednisone | Prednisone | 56 | 33 |
| Cefuroxime | Cefuroxime Axetil | 54 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 14 |
| Famotidine | Famotidine | 53 | 18 |
| Atenolol | Atenolol | 52 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Alprazolam | Alprazolam | 47 | suppressed |
| Mupirocin | Mupirocin | 46 | 31 |
| Tramadol Hcl | Tramadol Hcl | 44 | 14 |
| Finasteride | Finasteride | 43 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Allopurinol | Allopurinol | 35 | 12 |
| Montelukast Sodium | Montelukast Sodium | 35 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Azithromycin | Azithromycin | 28 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | 14 |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Clarithromycin Er | Clarithromycin | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 12 |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Pioglitazone-Glimepiride | Pioglitazone Hcl/Glimepiride | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $162.88 · 8 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, BRIXADI, MOUNJARO, Ozempic, PENBRAYA, PREVNAR 20, SUBLOCADE, TRUMENBA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error